-
Join 20 other subscribers
Categories
- ADME
- Bioactivation
- Biotransformation
- Blood Brain Barrier
- Carcinogens
- Central Nervous System (CNS)
- Chemistry
- Company
- Conjugation Reactions
- Covalent Binding
- Cytochrome P450
- Definitions
- Disease
- DNA Adducts
- Drug Design
- Drug Drug Interaction (DDI)
- Drug Metabolism
- Drug Safety
- Drug Target
- Drugs
- Heterocycles
- Human Liver Microsomes(HLM)
- Idiosyncratic Effect
- Immune Response
- In Vitro/In Vivo Correlation
- Introduction
- Mass Spectrometry
- Mechanism-Based Inhibition (MBI)
- Med Chem
- Metabolic Stability
- Metabolite Identification (MetID)
- Metabolite Prediction
- Metabolite Profiling
- Metabolomics
- Mutagens
- Natrual Products
- Non-P450 enzymes
- P450 Phenotyping
- Pharmacokinetics (PK)
- Phase 2 Metabolism
- Physicochemical Properties
- Protein Adducts
- Radioisotope Label
- Reactive Intermediates
- SAR
- Solvent Effects
- Time-dependent Inhibition (TDI)
- Toxicity
- Uncategorized
Recently Viewed Posts
- Metabolically Stable tert-Butyl Replacement ACS Med Chem Lett 2013
- Deuterated Clopidogrel Analogues as a New Generation of Antiplatelet Agents ACS Med Chem Lett 2013
- Thiolactone Sulfoxides as New Reactive Metabolites Acting as Bis-Electrophiles: Implication in Clopidogrel and Prasugrel Bioactivation CRT 2013
- Which Metabolites Circulate? Minireview DMD 2013
- Boronic Acid-Containing Proteasome Inhibitors: Alert to Potential Pharmaceutical Bioactivation CRT 2013
Blogs I Follow
Daily Archives: October 3, 2012
Can In Vitro Metabolism-Dependent Covalent Binding Data Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis Using Human Hepatocytes and Liver S-9 Fraction by scientists from Pfizer on CRT 2009
Bauman, J. N., et al. Chem. Res. Toxicol., 2009, 22 (2), pp 332–340 An examination on whether or not that hepatotoxic drugs can be distinguished from nonhepatotoxic ones based on in vitro covalent binding data carried out by researcher from Pfizer.
Posted in Covalent Binding, Drug Safety, Toxicity
Tagged Covalent Binding, Drug Safety
Leave a comment
Can In Vitro Metabolism-Dependent Covalent Binding Data in Liver Microsomes Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis of 18 Drugs with Consideration of Intrinsic Clearance and Daily Dose by R. Scott Obach et al on CRT 2008
Obach, R. S., et al. Chem. Res. Toxicol., 2008, 21 (9), pp 1814–1822 A study on assessment of correlation of the amount of covalent binding formation and hepato-toxicity performed by scientists from Pfizer.
Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure−Activity Relationships and Discovery Strategies To Mitigate Drug−Drug Interaction Risks by scientists from Pfizer on JMC 2012
Orr, S. T. M., et al. J. Med. Chem., 2012, 55 (11), pp 4896–4933 A recent review on MBI of cytochrome P450: SAR and mitigating DDI.
Improving Drug Candidates by Design: A Focus on Physico-chemical Properties As a Means of Improving Compound Disposition and Safety by Nicholas A. Meanwell on CRT 2011
Meanwell, N., Chem. Res. Toxicol., 2011, 24 (9), pp 1420–1456 A review on improving compound disposition and safety by optimizing the physico-chemical properties.
Posted in Drug Safety, Med Chem, Physicochemical Properties
Tagged ADME, Drug Safety, Med Chem, Review
Leave a comment
Cytochrome P450 and Chemical Toxicology by F. Peter Guengerich on CRT 2008
Guengerich, F. P., Chem. Res. Toxicol., 2008, 21 (1), pp 70–83 A nice review on cytochrome P450 and chemical toxicology by F. Peter Guengerich in 2008 on CRT.
ADMETchemist 